Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study
Hepatology, Volume 46, No. 2, Year 2007
Notification
URL copied to clipboard!
Description
Although steatosis is a common histological feature in chronic hepatitis C (CHC), nonalcoholic steatohepatitis (NASH) has not yet been clearly characterized in this context. The aim of this prospective study was to investigate the characteristics of patients with NASH and CHC. Biopsies were categorized as CHC alone (178 patients [57%]), CHC+steatosis (94 patients [34%]), or CHC+NASH (24 patients [9%]). Patients with CHC+NASH had significantly higher AST and triglyceride levels and lower high-density lipoprotein (HDL) cholesterol or total cholesterol than patients with CHC+steatosis. They also showed more steatosis and higher METAVIR fibrosis stage than patients with CHC+steatosis. Genotype 3 was more frequent in patients with CHC+NASH than in patients with CHC+steatosis or CHC alone. Patients with genotype 3 and CHC+NASH were similar to those with CHC+steatosis or with CHC alone according to triglyceride or the homeostasis model for assessment of insulin resistance (HOMA-IR), whereas in patients with genotype 1, HOMA-IR and triglyceride increased progressively from CHC alone to CHC+steatosis to CHC+NASH. In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor. Conclusion: Patients with CHC+NASH differ significantly from those with CHC+steatosis and CHC alone in terms of biological and metabolic parameters and more advanced histopathological lesions. NASH is more common in genotype 3 and is not associated with metabolic dysfunctions in this subgroup, suggesting that NASH may complicate steatosis in CHC irrespective of etiology of steatosis. Copyright © 2007 by the American Association for the Study of Liver Diseases.
Authors & Co-Authors
Bédossa, Pierre
France, Clichy
Hôpital Beaujon
Moucari, Rami
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Chelbi, Emna
France, Clichy
Hôpital Beaujon
Asselah, Tarik
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Paradis, Valerie
France, Clichy
Hôpital Beaujon
Vidaud, Michel
France, Clichy
Hôpital Beaujon
Cazals-Hatem, Dominique L.
France, Clichy
Hôpital Beaujon
Boyer, Nathalie
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Valla, Dominique Charles
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Marcellin, Patrick M.
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Statistics
Citations: 128
Authors: 10
Affiliations: 2
Identifiers
Doi:
10.1002/hep.21711
ISSN:
02709139
Research Areas
Genetics And Genomics
Infectious Diseases
Noncommunicable Diseases
Study Design
Cohort Study